Jinyu bio-technology: The industry is in the lowest valley period in history. New products next year will contribute to revenue growth | Directly addressing the earnings conference.
①At the performance briefing, jinyu bio-technology's chairman Zhang Chongyu frankly admitted that the industry is currently experiencing the lowest trough in history; ②The company stated that the competition in the pig vaccine sector is intense, and it will maintain its market share. Several new vaccines will be launched in the next two years. It is expected that the new products next year will contribute to a certain increase in revenue.
Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference
① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.
The first domestically produced ADC drug has been fully approved for marketing in China. Kelunbote takes the lead. | Quick announcement
① Sichuan Kelun Pharmaceutical's holding subsidiary Kelun Botai has received domestic approval for the marketing of Lukanasatuzumab. ② This drug is used for the treatment of unresectable locally advanced or metastatic breast cancer and is the first domestically produced ADC to receive full approval for marketing in the country. ③ Two additional new drug applications for Lukanasatuzumab have been accepted by the NMPA.
Is Guangxi Wuzhou Zhongheng Group planning to sell the controlling stake of Chongqing Lummy Pharmaceutical after years of consecutive losses? | Quick read announcement
①Guangxi Wuzhou Zhongheng Group intends to transfer the shares held directly in Chongqing Lummy Pharmaceutical through public solicitation, and the controlling shareholder and actual controller of the latter may change. ②The story of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019 and became a major shareholder of Chongqing Lummy Pharmaceutical in April of the following year, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical since then. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous loss-making state.
TJ Darentang USD: Wang Lei replaces Zhang Mingrui as the chairman, the company's development global strategy "will not change" | Speed reading announcement
① Zhang Mingrui applied to resign as the chairman, director, and chairman of the global strategy committee of tj darentang usd due to work changes. ② Wang Lei, the general manager, took over as chairman, with company officials stating that the enterprise development strategy "will not change".
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.